Ritonavir [155213-67-5]
Cat# T1525-500mg
Size : 500mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Ritonavir
(Synonyms: RTV, ABT 538, Abbott 84538, A 84538) Copy Product Info
Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.
Cas No. 155213-67-5
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.96%
Color:White
COA HNMR LCMS
Product Introduction
Ritonavir AI Summary
Ritonavir demonstrates potent bioactivity against HIV-1 protease with a high binding affinity, indicated by a Ki value of 0.37 nM. It shows strong antiviral activity against HIV-1, with an effective concentration (IC90) of 150.0 nM in MT-4 cells. Its inhibitory activity extends to various mutant strains of the virus, exhibiting resistance values ranging from 2.4 to 30.0 fold, depending on the specific strain. The compound also exhibits pharmacokinetic properties with high oral bioavailability in rats, showing a maximum plasma concentration (Cmax) of 2600.0 nM and a moderate half-life of 1.2 hours. Furthermore, Ritonavir inhibits CYP3A4 enzyme activities, as demonstrated by an IC50 of 50.0 nM. Additionally, it shows inhibitory activity against ritonavir and nelfinavir-resistant HIV-1 strains, with EC50 values of 16.0 nM and 220.0 nM respectively, suggesting its potential as a promising candidate for HIV therapy..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450. |
| In vivo | Ritonavir is a potent inhibitor of CYP3A-mediated biotransformation (terfenadine hydroxylation, IC50 of 0.14 mM; 17alpha-ethynylestradiol 2-hydroxylation, IC50 of 2 mM; nifedipine oxidation, IC50 of 0.07 mM).Ritonavir is a a potent inhibitor of CYP3A4-mediated testicular 6β-hydroxylation (Ki: 19 nM), and also inhibited hydroxylation by toluenesulfonylurea (IC50: 4.2 μM).Ritonavir also inhibited CYP2D6 (IC50: 2.5 mM) and CYP2C9/10 (IC50: 8.0 mM)-mediated responses.Ritonavir Ritonavir increased the cellular activity of uninfected human PBMC cultures.Ritonavir inhibited p-glycoprotein-mediated saquinavir solubilization (IC50: 0.2 μM), suggesting that Ritonavir has a high affinity for p-glycoprotein.Ritonavir significantly inhibited the metabolism of human hepatic microsomes ABT-378 (Ki: 13 nM). Ritonavir binding to ABT-378 ( in 3:1 and 29:1 ratios) was able to inhibit CYP3A (IC50: 1.1 and 4.6 μM). In cultures of uninfected human PBMCs, Ritonavir significantly reduced the susceptibility of PBMCs to apoptosis (associated with low levels of caspase-1 expression), decreased caspase-3 activity, and reduced membrane-bound protein staining. Ritonavir inhibited the induction of tumor necrosis factor produced by PBMCs and monocytes at nontoxic concentrations in a time- and dose-dependent manner. |
| Synonyms | RTV, ABT 538, Abbott 84538, A 84538 |
| Molecular Weight | 720.94 |
| Formula | C37H48N6O5S2 |
| Cas No. | 155213-67-5 |
| Smiles | CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1 |
| Relative Density. | 1.239 g/cm3 |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 242.5 mg/mL (336.37 mM), Heating is recommended.  Ethanol: 7.21 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (3.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||